Screener
Halozyme Therapeutics HALO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | 54,989 | 39,778 | 85,267 | 65,511 |
| Net income | $229,913 | $165,160 | $379,962 | $283,255 |
| Earnings per share | ||||
| Basic | $1.96 | $1.36 | $3.23 | $2.32 |
| Diluted | $1.90 | $1.33 | $3.11 | $2.26 |
| Weighted average common shares outstanding | ||||
| Basic | 117,274 | 121,343 | 117,707 | 122,274 |
| Diluted | 121,215 | 124,158 | 122,092 | 125,452 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's EPS (diluted)?
- Halozyme Therapeutics (HALO) reported EPS (diluted) of $1.90 in Q2 2026.
- How has Halozyme Therapeutics's EPS (diluted) changed year-over-year?
- Halozyme Therapeutics's EPS (diluted) increased by 42.9% year-over-year, from $1.33 to $1.90.
- What is the long-term trend for Halozyme Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2024), Halozyme Therapeutics's EPS (diluted) has grown at a 7.6% compound annual growth rate (CAGR), from $2.75 to $3.43.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Halozyme Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude